Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium (TACL) Marqibo® ALL study

T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

This study aims to evaluate the side effects (good and bad) of giving Vincristine Suflate Liposome Infection (also known as Marqibo®) - a drug approved for leukemia treatment in adults but that is experimental in children - with other standard chemotherapy drugs and to measure how effective the combination is at treating children and young adults with leukemia that has come back after initial treatment.

Study Details
Clinical Trials Government Identifier
Marqibo chemotherapy, ALL, acute lymphoblastic leukemia, relapse, vincristine sulfate, leukemia, cancer
Study Type
Drug Treatment
Age 1 to 21 with leukemia (ALL) that has returned after an initial response to treatment
Does this study also recruit healthy volunteers?
Enrollment Status
Coordinator Contact
Ellynore Florendo
Contact Email
Coordinator Contact
Meg Fender